AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02530320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib will be administered orally at a dose of 125 mg/day, until disease progression, unacceptable adverse side effects or study end.
Study NCT03506646 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will be given a gelatin tablet to serve as the control condition. This will be a double-blinded, randomized, cross-over design to examine the effects of beetroot juice on endothelial function, leg function, and thermoregulation.
Study NCT03506646 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beet root juice
Description: Beet root juice serves as a mode of dietary nitrate supplementation. This will be a double-blinded, randomized, cross-over design to examine the effects of beetroot juice on endothelial function, leg function, and thermoregulation.
Study NCT03280563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody
Description: Atezolizumab will be given as 840 milligrams (mg) via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle. This regimen will apply to all arms except when given with entinostat in Stage 1, or exemestane or tamoxifen in Stage 2, in which atezolizumab will be given as 1200 mg via IV infusion on Day 1 of each 21-day cycle.
Study NCT03280563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be given as 10 milligrams per kilogram (mg/kg) via IV infusion on Days 1 and 15 of each 28-day cycle in the regimen containing fulvestrant. When given with exemestane or tamoxifen, bevacizumab will be given as 15 mg/kg via IV infusion on Day 1 of each 21-day cycle.
Study NCT03280563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Entinostat will be given as 5 mg orally once a week on Days 1, 8 and 15 of each 21-day cycle.
Study NCT03280563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane will be given as 25 mg orally QD in each 21-day cycle.
Study NCT03280563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant will be given as 500 mg intramuscularly on Days 1 and 15 of Cycle 1 and thereafter on Day 1 of each 28-day cycle.
Study NCT03280563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant will be given as 500 mg intramuscularly on Days 1 and 15 of Cycle 1 and thereafter on Day 1 of each 28-day cycle.
Study NCT03280563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Ipatasertib will be given as 400 mg orally QD on Days 1-21 of each 28-day cycle.
Study NCT03280563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Tamoxifen will be given as 20 mg orally QD in each 21-day cycle.
Study NCT03280563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib will be given as 150mg twice daily during each 28-day cycle.
Study NCT05043324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AntiCov-220 (1)
Description: The daily maintenance, AntiCov-220 (1) dose is to take 3 times a day, 1 tablet each time.
Study NCT05043324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AntiCov-220 (2)
Description: The daily maintenance, AntiCov-220 (2) dose is to take 3 times a day, 1 tablet each time.
Study NCT05165277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phosphate Buffer Solution
Description: Phosphate-buffered saline (abbreviated PBS) is a buffer solution commonly used in biological research. It is a water-based salt solution containing disodium hydrogen phosphate, sodium dihydrogen phosphate. The buffer helps to maintain a constant pH. The osmolarity and ion concentrations of the solutions match those of the human body (isotonic).
Study NCT05165277 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate Buffer Solution
Description: Phosphate-buffered saline (abbreviated PBS) is a buffer solution commonly used in biological research. It is a water-based salt solution containing disodium hydrogen phosphate, sodium dihydrogen phosphate. The buffer helps to maintain a constant pH. The osmolarity and ion concentrations of the solutions match those of the human body (isotonic).
Study NCT02118896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK506E
Description: oral
Study NCT05179434 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retrograde renal graft reperfusion
Description: Retrograde venous reperfusion of the renal graft during the kidney transplant procedure with consequent arterial reperfusion
Study NCT05179434 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional antegrade renal graft reperfusion (without retrograde reperfusion)
Description: Conventional arterial antegrade renal graft reperfusion during the kidney transplant procedure
Study NCT03310606 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dosage of serum and peritoneal of the B lactam used for antibiotic treatment
Description: Dosage of serum and peritoneal of the B lactam used B lactam concerning are : CEFTRIAXONE, CEFOTAXIME, PIPERACILLINE/TAZOBACTAM, IMIPENEM
Study NCT00244881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib maleate
Description: Given orally
Study NCT00244881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04484987 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 9 hours daily eating window
Description: Participants assigned to the TRE group will have to consume all their daily meals and snacks during a 9-hour window for 12 weeks.
Study NCT04484987 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 15 hours daily eating window
Description: Participants assigned to the control group will have to consume all their daily meals and snacks during a 15-hour window for 12 weeks.
Study NCT02572271 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rubins Mastopexy
Description: The surgical technique described by Rubin is performed. No other intervention.
Study NCT02572271 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LOPOSAM
Description: The surgical technique LOPOSAM is performed. No other intervention.
Study NCT02841137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: comparison of different dosages of drug towards the active comparator
Study NCT03126682 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Wellbutrin SR 300Mg Extended-Release Tablet
Description: Wellbutrin SR 300Mg Extended-Release Tablet
Study NCT04851977 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Respiratory Syncytial Vaccine
Description: BARS13 low dose (one dose of 10 μg rRSV-G protein/10 μg CsA by IM injection to the deltoid region of one arm, and one dose of placebo \[saline/mannitol\] by IM injection to the deltoid region of the other arm, given sequentially).
Study NCT01048138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biperiden Lactate
Description: 5mg IV(in the vein)every 6 hours for 10 days
Study NCT01048138 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5mg IV(in the vein)every 6 hours for 10 days
Study NCT02681926 — intervention group
Intervention type: PROCEDURE
Intervention: VISITAG
Description: Paroxysmal atrial Fibrillation (PAF) ablation with contact force technology
Study NCT01607034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexpramipexole
Description: 150 mg single dose
Study NCT04008134 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHoBI7 health facility program
Description: The CHoBI7 health facility program focuses on promoting handwashing with soap and water treatment to diarrhea patients and their household members during the one-week period after the patient is admitted to the health facility, when their household is at highest risk for diarrheal diseases. The CHoBI7 program includes: (1) a WASH pictorial module delivered by a health worker bedside to diarrhea patient and their household members in a health facility on handwashing with soap, water treatment, and safe water storage; and (2) a diarrhea prevention package containing chlorine tablets for water treatment, a soapy water bottle (water and detergent powder), a handwashing station, and a water vessel with a lid and tap for safe drinking water storage. Households are instructed to boil their water once their supply of chlorine tablets is completed.
Study NCT04008134 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHoBI7 mHealth program
Description: The CHoBI7 mHealth (mobile health) program targets five key behaviors: (1) preparing soapy water using water and detergent powder; (2) handwashing with soap at food and stool related events; (3) treating household drinking water using chlorine tablets during the one week high risk period after the diarrhea patient in the household was admitted to the health facility; (4) safe drinking water storage in a water vessel with a lid and tap; and (5) heating of household drinking water until it reaches a rolling boil after the one week high risk period. Participant households receive bi-weekly voice and text messages from the CHoBI7 mHealth program over a 12-month period. These mobile messages are sent using the VIAMO platform (www.viamo.io).
Study NCT04008134 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHoBI7 home visit program
Description: The CHoBI7 home visit program involves two, 30-minute home visits conducted during the week after the index diarrhea patient was recruited at the health facility. A health worker reinforces the content of the CHoBI7 health facility program in the participant's home.
Study NCT01736852 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRB
Description: Labor induction using the CRB
Study NCT01736852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitocin
Description: Labor induction using Pitocin
Study NCT01736852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pitocin
Description: Labor induction using Pitocin
Study NCT00870311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Description: 300mg PO, three times daily with dose titrated to obtain a therapeutic plasma level of 0.8 to 1.2meq/L) over the first week of treatment. Total duration is a minimum of 3 weeks. Medication is dispensed in the form of blinded research capsules.
Study NCT02397083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given PO
Study NCT02397083 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02397083 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-Releasing Intrauterine System
Description: Placed in the uterus
Study NCT04851977 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Respiratory Syncytial Vaccine
Description: BARS13 high dose (IM injection of 10 μg rRSV-G protein/10 μg CsA administered to the deltoid region of each arm \[one injection of 10 μg rRSV-G protein/10 μg CsA per arm\], given sequentially). The high dose is twice the strength of the low dose.
Study NCT04851977 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (IM injection of saline/mannitol administered to the deltoid region of each arm \[one injection per arm\], given sequentially).
Study NCT04480164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NDMC
Description: Repeated oral administration of ascending daily doses of NDMC (40mg, 60mg,120mg/day) vs placebo in 3 sequential cohorts
Study NCT04480164 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NDMC
Description: Repeated oral administration of ascending daily doses of NDMC (40mg, 60mg,120mg/day) vs placebo in 3 sequential cohorts
Study NCT01732835 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HAART 300 Annuloplasty Device
Description: Implantation of HAART 300 Annuloplasty Device for aortic valve repair
Study NCT04136106 — intervention group
Intervention type: DRUG
Intervention: IL-2
Description: IL-2 is a medicine which can use in autoimmune disease, infection or cancer with different dose. Low-dose IL-2 preferentially used in autoimmune disease, such as SLE. Our enrolled SLE patients will divided into two groups depend on whether use IL-2 or not, combined with corticosteroid and immunosuppressor.
Study NCT01369628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept
Description: 1. Regimen 1: Atacicept 25 mg weekly for 12 weeks~2. Regimen 2: Atacicept 75 mg weekly for 12 weeks~3. Regimen 3: Atacicept 150 mg weekly for 12 weeks
Study NCT00583492 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad5-yCD/mutTKSR39rep-ADP
Description: Ad5-yCD/mutTKSR39rep-ADP (1 x 10\^12 vp) on day 1 Plus Radiation - 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy Plus 2 week course (weekdays only) of 5-FC and vGCV prodrug therapy
Study NCT00583492 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT
Description: 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy
Study NCT00380640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim
Description: This group will receive the active intervention (trimethoprim) first, followed by the placebo.
Study NCT00380640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim
Description: This group will start the study with placebo, followed by the active intervention (trimethoprim).
Study NCT01070810 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: D5W
Description: Dextrose 5%
Study NCT01070810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiamine
Description: Thiamine 200mg in 50ml D5W
Study NCT02533882 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Movement to Music
Study NCT02533882 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adapted Yoga
Study NCT00187798 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metformin HCl
Description: Subjects will be given a single oral dose in tablet form containing 850 mg of metformin
Study NCT02323724 — intervention group
Intervention type: GENETIC
Intervention: BRAF V600E mutation by pyrosequencing technique
Study NCT04329962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blueberry Powder Food Product
Description: Consume blueberry powder confection
Study NCT04329962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Consume blueberry extract confection
Study NCT04329962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03880578 — intervention group
Intervention type: DRUG
Intervention: Levothyroxine Sodium
Description: thyroid hormone replacement
Study NCT01544712 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: core decompression with autologous bone marrow implantation
Description: core biopsy with injection of 40 ml concentrated autologous bone marrow.
Study NCT01544712 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: core decompression of the femoral head
Description: core biopsy with injection of 40 ml saline solution in place of bone marrow.
Study NCT04212507 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The serum level of Claudin-3 and intestinal Fatty acid binding protein
Description: The serum level of Claudin-3 and intestinal Fatty acid-binding protein between patients with psoriasis and controls Understanding the interplay between microbiota, gut barrier and inflammation may contribute to the development of new methods of preventing onset or exacerbations of psoriasis and new therapeutic approach for psoriasis.
Study NCT03569956 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 556 Razor
Description: In the Razor group, subjects will use the 556 Razor with their regular shaving products, and shave at least 5 or more times per week. In the Regimen group, subjects will use the 556 Razor, Pre-Shave Gel, Cleansing brush and Shaving Gel, and shave at least 5 or more times per week. All subjects will be given the 556 Razors during the 12-week study. The Regimen group will also be given the Pre-Shave Gel, Cleansing Brush, and Shaving Gel.
Study NCT03569956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 556 Razor
Description: In the Razor group, subjects will use the 556 Razor with their regular shaving products, and shave at least 5 or more times per week. In the Regimen group, subjects will use the 556 Razor, Pre-Shave Gel, Cleansing brush and Shaving Gel, and shave at least 5 or more times per week. All subjects will be given the 556 Razors during the 12-week study. The Regimen group will also be given the Pre-Shave Gel, Cleansing Brush, and Shaving Gel.
Study NCT03083288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FluorThanatrace
Description: \[18F\]FluorThanatrace is a radiotracer for PET/CT
Study NCT00890461 — intervention group
Intervention type: RADIATION
Intervention: CT scan of the chest without contrast
Description: Patients consenting to participate in the study may also undergo a baseline CT scan of the cest without contrast to allow for the geometrical characterization of their intracardiac electrodes from the ICD system in relation to the position of the 12-lead surface ECG electrodes which would be applied to the chest prior to the CT scan. This scan involves a small amount of radiation, a dose of approximately 1 rem. For comparison, radiation workers are permitted, by federal regulation, a maximum annual radiation exposure of 20 rems to the most sensitive organs of their body.
Study NCT05116735 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic partial cystectomy with omentoplasty
Description: laparoscopic partial cystectomy with omentoplasty
Study NCT01075659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Two single doses of experimental Nicotine Replacement Therapy (NRT) 2 mg, with five hours between treatments. Seven hours duration of total follow-up period
Study NCT01075659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: Two single doses of Nicotine Lozenge 2 mg, with five hours between treatments. Seven hours duration of total follow-up period.
Study NCT01075659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: Two single doses of Nicotine Lozenge 4 mg, with five hours between treatments. Seven hours duration of total follow-up period.
Study NCT04177108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab was administered as per the dosage regimen mentioned in arm descriptions.
Study NCT04177108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Ipatasertib was administered as per the dosage regimen mentioned in arm descriptions.
Study NCT04177108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel was administered as per the dosage regimen mentioned in arm descriptions.
Study NCT04177108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Atezolizumab
Description: Placebo was administered as per the dosage regimen mentioned in arm descriptions.
Study NCT04177108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Ipatasertib
Description: Placebo was administered as per the dosage regimen mentioned in arm descriptions.
Study NCT02785367 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cord blood samples
Description: After delivery, 8 cord blood samples will be taken from the umbilical cord in 8 syringes of about 3 ml, washed with Heparin (Designated syringes exist in the delivery room). 4 syringes will be stored in room temperature. Thermometer will be attached to any sample, and temperature values will be indicated before any measurement.~The samples will be measured in a gas measurement device, in 4 time points: at the birth, after 15 minutes, after 30 minutes and after 60 minutes from the birth.
Study NCT00945516 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bona stent® (Flared end FCSEMS)
Description: Flared end FCSEMS for benign bile duct stricture will be inserted with ERCP.
Study NCT00945516 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hanarostent® (Anchoring FCSEMS)
Description: Anchoring FCSEMS for benign bile duct stricture will be inserted with ERCP.
Study NCT01856972 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Instrument Assisted Soft Tissue Mobilization
Description: IASTM treatment: will be performed with the sound assisted soft tissue mobilization tool #5. Patient will be placed in the prone position with the ankle in a relaxed position. The treating therapist will perform 10 scanning strokes in the caudal, cephalic, medial, lateral directions for a total of 40 strokes over the Gastrocnemius/Soleus complex. The therapist can then perform more concentrated strokes in areas noted by the therapist as tight, with a maximum treatment time of 5 minutes.